22nd Century Group achieves debt-free status and $17.6M in 2025 revenue

22nd Century Group (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to tobacco harm reduction and reduced-nicotine tobacco, today reported its financial results for the fourth quarter and full year ended December 31, 2025.

For the full year 2025, 22nd Century Group reported net revenues of $17.6 million, with $3.5 million generated in the fourth quarter.

The company recorded a net loss from continuing operations of $13.1 million for the year, which narrowed to $2.8 million in the fourth quarter.

This improvement in the quarterly bottom line reflects the successful execution of a comprehensive cost-reduction initiative implemented earlier in the fiscal year.

A major milestone of the 2025 fiscal year was the transformation of the company’s balance sheet.

22nd Century Group exited the year entirely debt-free, having eliminated more than $8 million in legacy debt obligations.

This was made possible by the successful recovery of a $9.5 million insurance settlement.

As of December 31, 2025, the company maintained a cash position of $7.1 million, providing a stable foundation for its 2026 commercial operations.

On the operational front, the company significantly expanded the market presence of its flagship VLN® (Very Low Nicotine) products.

Throughout 2025, 22nd Century Group secured new retail and state authorizations across multiple partner brands, increasing the availability of the only combustible cigarette to receive a "Modified Risk Tobacco Product" (MRTP) authorization from the FDA.